Free Trial

Diaceutics (DXRX) Competitors

Diaceutics logo
GBX 111.05 -3.95 (-3.44%)
As of 04/4/2025 11:53 AM Eastern

DXRX vs. AGL, YGEN, ABDX, PRM, GDR, VRCI, GENI, DMTR, LLAI, and LLA

Should you be buying Diaceutics stock or one of its competitors? The main competitors of Diaceutics include ANGLE (AGL), Yourgene Health (YGEN), Abingdon Health (ABDX), Proteome Sciences (PRM), genedrive (GDR), Verici Dx (VRCI), GENinCode (GENI), Deepmatter Group (DMTR), LungLife AI (LLAI), and LLA.L,0P0001T9GN,0 (LLA). These companies are all part of the "diagnostics & research" industry.

Diaceutics vs.

Diaceutics (LON:DXRX) and ANGLE (LON:AGL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, community ranking, risk, earnings, media sentiment, institutional ownership and dividends.

Diaceutics currently has a consensus target price of GBX 160, suggesting a potential upside of 44.08%. ANGLE has a consensus target price of GBX 40, suggesting a potential upside of 344.99%. Given ANGLE's higher possible upside, analysts clearly believe ANGLE is more favorable than Diaceutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Diaceutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
ANGLE
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Diaceutics has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, ANGLE has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500.

52.4% of Diaceutics shares are owned by institutional investors. Comparatively, 18.8% of ANGLE shares are owned by institutional investors. 34.3% of Diaceutics shares are owned by company insiders. Comparatively, 16.2% of ANGLE shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Diaceutics has higher revenue and earnings than ANGLE. Diaceutics is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Diaceutics£26.08M3.59-£2.84M-£3.37-32.93
ANGLE£2.44M11.86-£21.76M-£6.76-1.33

ANGLE received 168 more outperform votes than Diaceutics when rated by MarketBeat users. However, 88.24% of users gave Diaceutics an outperform vote while only 62.46% of users gave ANGLE an outperform vote.

CompanyUnderperformOutperform
DiaceuticsOutperform Votes
15
88.24%
Underperform Votes
2
11.76%
ANGLEOutperform Votes
183
62.46%
Underperform Votes
110
37.54%

Diaceutics has a net margin of -10.90% compared to ANGLE's net margin of -890.91%. Diaceutics' return on equity of -7.15% beat ANGLE's return on equity.

Company Net Margins Return on Equity Return on Assets
Diaceutics-10.90% -7.15% -6.06%
ANGLE -890.91%-76.01%-29.89%

In the previous week, Diaceutics had 1 more articles in the media than ANGLE. MarketBeat recorded 1 mentions for Diaceutics and 0 mentions for ANGLE. Diaceutics' average media sentiment score of 1.78 beat ANGLE's score of 0.00 indicating that Diaceutics is being referred to more favorably in the media.

Company Overall Sentiment
Diaceutics Very Positive
ANGLE Neutral

Summary

Diaceutics beats ANGLE on 13 of the 17 factors compared between the two stocks.

Remove Ads
Get Diaceutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DXRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DXRX vs. The Competition

MetricDiaceuticsDiagnostics & Research IndustryMedical SectorLON Exchange
Market Cap£93.72M£828.86M£5.24B£2.41B
Dividend YieldN/A5.44%4.87%4.95%
P/E Ratio-32.931.9021.18127.76
Price / Sales3.59305.28356.35257,920.01
Price / Cash3.1211.4238.1627.87
Price / Book2.422.806.234.33
Net Income-£2.84M£308.37B£3.20B£5.76B
7 Day Performance-9.90%-2.38%-8.32%2.05%
1 Month Performance-21.58%-8.11%-3.36%0.74%
1 Year Performance5.76%-7.76%2.72%92.67%

Diaceutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DXRX
Diaceutics
2.6577 of 5 stars
GBX 111.05
-3.4%
GBX 160
+44.1%
+5.8%£93.72M£26.08M-32.93151News Coverage
Positive News
AGL
ANGLE
N/AGBX 9.22
-0.3%
GBX 40
+333.8%
-26.6%£29.71M£2.44M-1.36650
YGEN
Yourgene Health
N/AN/AN/AN/A£16.43M£29.67M-51.50253
ABDX
Abingdon Health
N/AGBX 6.48
-0.3%
N/A-40.5%£12.55M£3.84M-15.7684Gap Up
PRM
Proteome Sciences
N/AGBX 3.70
-8.9%
N/A+24.6%£10.92M£10.88B-2.68240Gap Down
GDR
genedrive
N/AGBX 1.86
-2.4%
N/A-80.8%£10.53M£1.50M-0.5243
VRCI
Verici Dx
N/AGBX 2.87
+4.4%
N/A-61.8%£8.71M£5.91M-1.6619Gap Up
GENI
GENinCode
N/AGBX 3.07
+7.7%
N/A-71.3%£5.45M£2.67M-0.902,300
DMTR
Deepmatter Group
N/AN/AN/AN/A£1.33M£1.04M-0.11N/AGap Down
LLAI
LungLife AI
N/AGBX 1
-8.3%
N/A-96.9%£331,000.00£33,871.03-0.0815Gap Down
LLA
LLA.L,0P0001T9GN,0
N/AN/AN/AN/A£0.00N/A-8.3315Gap Down
High Trading Volume
Remove Ads

Related Companies and Tools


This page (LON:DXRX) was last updated on 4/5/2025 by MarketBeat.com Staff
From Our Partners